ホルモン避妊薬市場 - 世界の産業規模、シェア、動向、機会、予測、方法別、ホルモン別、地域別、競合別セグメント、2020～2030年

ホルモン避妊薬の世界市場規模は2024年に172億5,000万米ドルとなり、予測期間中のCAGRは6.78%で2030年には255億7,000万米ドルに達すると予測されています。

ホルモン避妊薬の世界市場は、経口避妊薬の使用に関する意識の高まりと、意図しない妊娠の防止や人口抑制の利点により、世界のさまざまな地域でホルモン避妊薬の需要が大幅に増加し、大きな成長を遂げています。さらに、ホルモン避妊薬の採用が大幅に増加しており、幅広い年齢層の女性の間で安全な生活を送ることへの意識が高まっていることから、各種ホルモン避妊法の需要は今後さらに拡大すると見込まれます。例えば、2021年4月、Mayne Pharma社が販売する妊娠を予防するためのドロスピレノンとエステトロールの配合錠剤Nextstellisが食品医薬品局から承認されましたが、これは天然由来のエストロゲンを含む最初の配合錠剤の1つです。

市場促進要因

家族計画およびリプロダクティブ・ヘルスを促進するための政府イニシアチブの高まり

主な市場課題

ホルモン避妊薬に関連する健康リスクと副作用

主要市場動向

長時間作用型可逆的避妊薬（LARC）への嗜好の高まり

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 臨床試験分析

第6章 世界のホルモン避妊薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 方法別（ピル、子宮内避妊器具、注射剤、膣リング、インプラント、その他）
  • ホルモン別（ホルモン併用避妊薬とプロゲスチン単独避妊薬）
  • 地域別
  • 企業別（2024年）
• 市場マップ
  • 方法別
  • ホルモン別
  • 地域別

第7章 北米のホルモン避妊薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第8章 欧州のホルモン避妊薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第9章 アジア太平洋地域のホルモン避妊薬市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第10章 南米のホルモン避妊薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第11章 中東・アフリカのホルモン避妊薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第12章 市場力学

• 促進要因
• 課題

第13章 市場動向と発展

• 最近の動向
• 合併と買収
• 製品上市

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威/サービス

第15章 SWOT分析：世界のホルモン避妊薬市場

第16章 競合情勢

• Abbvie, Inc.
• Afaxys, Inc.
• Teva Pharmaceuticals Industries Ltd.
• Bayer AG
• Merck KGaA
• Organon Group of Companies
• Pfizer Inc.
• Johnson & Johnson Services, Inc.
• Lupin Pharmaceuticals, Inc.
• Pregna International Ltd.

第17章 戦略的提言

第18章 調査会社について・免責事項

Global Hormonal Contraceptives Market was valued at USD 17.25 Billion in 2024 and is expected to reach USD 25.57 Billion by 2030 with a CAGR of 6.78% during the forecast period. The global market for Hormonal Contraceptives is experiencing significant growth, driven by the growing awareness regarding usage of oral contraceptive and its benefits for preventing the unintended pregnancy and population control significantly increased the demand for hormonal contraceptives across different parts of the globe. Additionally, ahavetion of hormonal contraceptives has significantly increased and increasing awareness among women of different age group for leading the safe life is further expected to increase the demand for different hormonal contraceptives procedures, thereby fuelling the market growth. For instance, in April 2021, the Food and Drug Administration approved a combination of drospirenone and estetrol tablet Nextstellis marketed by Mayne Pharma for preventing pregnancy, one of the first combination pills containing naturally occurring estrogen.

Key Market Drivers

Rising Government Initiatives to Promote Family Planning and Reproductive Health

One of the primary drivers of growth in the global hormonal contraceptives market is the significant investment by governments and international health organizations in reproductive health and family planning programs. Hormonal contraceptives-including oral pills, patches, injections, implants, and vaginal rings-form the cornerstone of modern contraception. Their widespread availability and integration into public health systems are largely supported by government policies that aim to reduce unintended pregnancies, maternal mortality, and child morbidity. The World Health Organization (WHO) states that around 257 million women globally who want to avoid pregnancy are not using safe or modern contraceptive methods. To address this unmet need, numerous governments have scaled up access to hormonal contraceptives through national programs. For instance, the U.S. federal Title X Family Planning Program supports clinics in offering affordable or free birth control to low-income individuals. According to the Office of Population Affairs (OPA), Title X clinics served 1.5 million individuals in 2022 alone, and over 99% of those clients received contraceptive services.

In developing countries, such as India, the Ministry of Health and Family Welfare operates the National Family Planning Program, which provides subsidized contraceptives through public health centers. As of 2023, the Indian government distributed over 20 million cycles of oral contraceptive pills under its Mission Parivar Vikas scheme. These expansive efforts ensure continuous market demand for hormonal contraceptives and stimulate innovation and supply chain efficiency. In effect, public health policies aimed at increasing contraceptive prevalence are driving hormonal contraceptive market growth across regions.

Key Market Challenges

Health Risks and Side Effects Associated with Hormonal Contraceptives

Despite their widespread use and effectiveness, hormonal contraceptives are associated with various health risks and side effects, which pose a significant challenge to market growth. Hormonal contraceptives function by altering a woman's hormone levels to prevent ovulation, and this hormonal interference can lead to adverse effects such as mood swings, weight gain, nausea, headaches, and menstrual irregularities. More serious risks include an increased likelihood of blood clots, cardiovascular complications, and, in rare cases, certain types of cancer. A study by the National Cancer Institute (NCI) reported a slight increase in the risk of breast and cervical cancer among long-term users of hormonal contraceptives, although they may reduce the risk of ovarian and endometrial cancers.

In 2019, the U.S. Food and Drug Administration (FDA) updated warnings on combined hormonal contraceptives (CHCs) about the risk of venous thromboembolism (VTE), especially for products containing drospirenone. Similarly, regulatory agencies in Europe, such as the European Medicines Agency (EMA), have recommended stronger warnings and educational efforts to ensure informed use. Concerns about side effects can lead to discontinuation or switching to non-hormonal methods, particularly in high-risk populations such as smokers over 35, obese individuals, and those with hypertension or a family history of thrombotic disorders. These health considerations reduce user confidence and affect market penetration, especially among new adopters. As awareness of potential adverse effects grows, particularly through social media and health advocacy platforms, it may hinder widespread adoption unless offset by education, personalized medical guidance, and the development of safer formulations.

Key Market Trends

Increasing Preference for Long-Acting Reversible Contraceptives (LARCs)

A prominent trend reshaping the hormonal contraceptives landscape is the growing preference for Long-Acting Reversible Contraceptives (LARCs) such as hormonal intrauterine devices (IUDs) and subdermal implants. These methods offer extended protection ranging from three to ten years, minimal maintenance, and high efficacy-qualities that are increasingly appealing to women globally, particularly those seeking convenience and long-term reproductive autonomy. According to the U.S. Centers for Disease Control and Prevention (CDC), LARCs have the lowest failure rates among contraceptive methods-less than 1%-compared to 7% for oral contraceptive pills. This reliability, combined with a low requirement for user adherence, has fueled rapid adoption, especially in developed countries with well-established healthcare systems.

Government programs are also promoting LARCs as part of comprehensive reproductive healthcare. For instance, the UK's National Health Service (NHS) includes hormonal IUDs in its publicly funded contraceptive offerings. In the U.S., state-level Medicaid expansion has been linked to increased access and uptake of LARCs, particularly in underserved populations. A report from the Kaiser Family Foundation found that the use of LARCs among U.S. women aged 15-44 increased from 8.5% in 2009 to 14% in 2020. In low- and middle-income countries, international bodies like UNFPA and USAID have rolled out LARC-focused initiatives to reduce unmet contraceptive needs. These global efforts, combined with innovations in hormonal implant technologies, are likely to sustain the rising demand for LARCs over the coming decade.

Key Market Players

• Abbvie, Inc.
• Afaxys, Inc.
• Teva Pharmaceuticals Industries Ltd.
• Bayer AG
• Merck KGaA
• Organon Group of Companies
• Pfizer Inc.
• Johnson & Johnson Services, Inc.
• Lupin Pharmaceuticals, Inc.
• Pregna International Ltd.

Report Scope:

In this report, the Global Hormonal Contraceptives Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hormonal Contraceptives Market, By Method:

• Pill
• Intrauterine Device
• Injectable
• Vaginal Ring
• Implant
• Others

Hormonal Contraceptives Market, By Hormone:

• Combination Hormonal Contraceptives
• Progestin Only

Hormonal Contraceptives Market, By Region:

• North America
  • United States
  • Mexico
  • Canada
• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
• Asia-Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Hormonal Contraceptives Market.

Available Customizations:

Global Hormonal Contraceptives Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

• 5.1. Ongoing Clinical Trials
• 5.2. Completed Clinical Trials
• 5.3. Terminated Clinical Trials
• 5.4. Breakdown of Pipeline, By Development Phase
• 5.5. Breakdown of Pipeline, By Status
• 5.6. Breakdown of Pipeline, By Study Type
• 5.7. Breakdown of Pipeline, By Region
• 5.8. Clinical Trials Heat Map

6. Global Hormonal Contraceptives Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Method (Pill, Intrauterine Device, Injectable, Vaginal Ring, Implant, Others)
  • 6.2.2. By Hormone (Combination Hormonal Contraceptives v/s Progestin Only)
  • 6.2.3. By Region
  • 6.2.4. By Company (2024)
• 6.3. Market Map
  • 6.3.1. By Method
  • 6.3.2. By Hormone
  • 6.3.3. By Region

7. North America Hormonal Contraceptives Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Method
  • 7.2.2. By Hormone
  • 7.2.3. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Hormonal Contraceptives Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Method
      • 7.3.1.2.2. By Hormone
  • 7.3.2. Canada Hormonal Contraceptives Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Method
      • 7.3.2.2.2. By Hormone
  • 7.3.3. Mexico Hormonal Contraceptives Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Method
      • 7.3.3.2.2. By Hormone

8. Europe Hormonal Contraceptives Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Method
  • 8.2.2. By Hormone
  • 8.2.3. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. France Hormonal Contraceptives Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Method
      • 8.3.1.2.2. By Hormone
  • 8.3.2. Germany Hormonal Contraceptives Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Method
      • 8.3.2.2.2. By Hormone
  • 8.3.3. United Kingdom Hormonal Contraceptives Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Method
      • 8.3.3.2.2. By Hormone
  • 8.3.4. Italy Hormonal Contraceptives Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Method
      • 8.3.4.2.2. By Hormone
  • 8.3.5. Spain Hormonal Contraceptives Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Method
      • 8.3.5.2.2. By Hormone

9. Asia-Pacific Hormonal Contraceptives Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Method
  • 9.2.2. By Hormone
  • 9.2.3. By Country
• 9.3. Asia-Pacific: Country Analysis
  • 9.3.1. China Hormonal Contraceptives Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Method
      • 9.3.1.2.2. By Hormone
  • 9.3.2. India Hormonal Contraceptives Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Method
      • 9.3.2.2.2. By Hormone
  • 9.3.3. Japan Hormonal Contraceptives Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Method
      • 9.3.3.2.2. By Hormone
  • 9.3.4. South Korea Hormonal Contraceptives Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Method
      • 9.3.4.2.2. By Hormone
  • 9.3.5. Australia Hormonal Contraceptives Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Method
      • 9.3.5.2.2. By Hormone

10. South America Hormonal Contraceptives Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Method
  • 10.2.2. By Hormone
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Hormonal Contraceptives Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Method
      • 10.3.1.2.2. By Hormone
  • 10.3.2. Argentina Hormonal Contraceptives Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Method
      • 10.3.2.2.2. By Hormone
  • 10.3.3. Colombia Hormonal Contraceptives Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Method
      • 10.3.3.2.2. By Hormone

11. Middle East and Africa Hormonal Contraceptives Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Method
  • 11.2.2. By Hormone
  • 11.2.3. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. South Africa Hormonal Contraceptives Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Method
      • 11.3.1.2.2. By Hormone
  • 11.3.2. Saudi Arabia Hormonal Contraceptives Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Method
      • 11.3.2.2.2. By Hormone
  • 11.3.3. UAE Hormonal Contraceptives Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Method
      • 11.3.3.2.2. By Hormone

12. Market Dynamics

• 12.1. Drivers
• 12.2. Challenges

13. Market Trends & Developments

• 13.1. Recent Developments
• 13.2. Mergers & Acquisitions
• 13.3. Product Launches

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products/Services

15. SWOT Analysis: Global Hormonal Contraceptives Market

16. Competitive Landscape

• 16.1. Abbvie, Inc.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (As Reported)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.7. SWOT Analysis
• 16.2. Afaxys, Inc.
• 16.3. Teva Pharmaceuticals Industries Ltd.
• 16.4. Bayer AG
• 16.5. Merck KGaA
• 16.6. Organon Group of Companies
• 16.7. Pfizer Inc.
• 16.8. Johnson & Johnson Services, Inc.
• 16.9. Lupin Pharmaceuticals, Inc.
• 16.10. Pregna International Ltd.

17. Strategic Recommendations

18. About Us & Disclaimer